Curi Bio’s preclinical platform integrates human iPSC-derived cells, tissue-specific biosystems, and AI/ML-enabled phenotypic screening data to accelerate the discovery of the next generation of medicines. Curi’s suite of human iPSC-derived products and services enable scientists to build more mature and predictive human iPSC-derived tissues—with a focus on cardiac, musculoskeletal, and neuromuscular models—for the discovery, safety testing, and efficacy testing of new drugs in development.